Published: 5 August 2026 | 6.00 AM
Last Updated: 5 August 2026 | 8.00 AM
IPO Snapshot
| Particulars | Details |
|---|---|
| Chanakya View | 🟢 Apply |
| Overall Rating | ⭐⭐⭐⭐☆ (4/5) |
| GMP Today | Updated Daily |
| Issue Size | Rs. 69.04 Crore |
| Price Band | Rs. 110 – Rs. 118 |
| Lot Size | 1,200 Shares |
| Minimum Retail Investment | Rs. 2,83,200 |
| IPO Opens | 12 August 2026 |
| IPO Closes | 14 August 2026 |
| Allotment | 17 August 2026 |
| Listing | 19 August 2026 |
| Exchange | NSE SME |
| Lead Manager | Smart Horizon Capital Advisors Pvt. Ltd. |
| Registrar | Purva Sharegistry (India) Pvt. Ltd. |
Investor Decision Box
| Question | Chanakya View |
|---|---|
| Suitable for Listing Gain? | 🟢 Yes, if GMP remains healthy |
| Suitable for Long-Term? | 🟢 Yes |
| Risk Level | Medium |
| Business Quality | ⭐⭐⭐⭐☆ |
| Financial Strength | ⭐⭐⭐⭐⭐ |
| Balance Sheet | ⭐⭐⭐⭐☆ |
| Valuation | ⭐⭐⭐⭐⭐ |
👉 | IPO GMP | IPO Reviews | IPO Subscription | IPO Allotment
Chanakya View
Pramodini Medicare Limited operates in one of India’s fastest-growing healthcare segments—diagnostic services. Unlike standalone pathology laboratories, the company offers an integrated portfolio covering radiology, clinical laboratory and nuclear medicine, serving government hospitals, private hospitals, PSUs and diagnostic centres across Tier I, II and III cities.
The company has reported excellent financial growth, with FY26 revenue increasing 64% to Rs. 63.38 crore and PAT rising 56% to Rs. 17.38 crore. Profitability is also impressive, with PAT Margin of 27.90%, EBITDA Margin of 49.61%, ROE of 39.08% and ROCE of 34.66%, reflecting efficient capital utilisation.
Another positive factor is the utilisation of IPO proceeds. Unlike many SME issues that primarily raise funds for working capital, Pramodini Medicare is using most of the fresh issue proceeds to purchase advanced medical equipment and expand diagnostic infrastructure, providing a visible growth trigger.
At the upper price band, the IPO is valued at a post-issue P/E of 14.97x, which appears reasonable considering its profitability, return ratios and growth profile.
Chanakya Recommendation: 🟢 Apply, subject to satisfactory Grey Market Premium (GMP) and subscription demand during the issue period.
About the Company
Established in 2000, Pramodini Medicare Limited is a technology-enabled diagnostic services company providing healthcare diagnostics across radiology, pathology and nuclear medicine.
The company operates through four diversified business models:
- Public-Private Partnership (PPP) with government hospitals
- Private hospital partnerships
- Strategic collaborations with PSUs
- Standalone diagnostic centres
Its diagnostic portfolio includes MRI, CT Scan, X-Ray, Ultrasound, Mammography, PET-CT, SPECT, Clinical Pathology, Biochemistry, Immunology and Microbiology.
As of 4 August 2026, the company operated 16 diagnostic centres across seven states, supported by a 24×7 teleradiology centre and central laboratory in Vijayawada.
Why This IPO Stands Out
✅ Operates in the fast-growing healthcare diagnostics sector.
✅ Diversified business model across government, private hospitals, PSUs and standalone centres.
✅ Excellent FY26 financial growth with 64% revenue growth and 56% PAT growth.
✅ Strong profitability with ROE 39.08% and ROCE 34.66%.
✅ IPO proceeds will fund expansion through purchase of advanced diagnostic equipment.
✅ Reasonable valuation of 14.97x post-issue P/E.
Key Risks
⚠ SME IPOs generally witness higher volatility and lower post-listing liquidity.
⚠ Business depends on renewal of PPP agreements and institutional contracts.
⚠ Diagnostic centres require continuous investment in technology and medical equipment.
⚠ Expansion plans may temporarily increase operating costs before generating additional revenue.
⚠ The healthcare diagnostics industry remains highly competitive.
Financial Snapshot (Rs. Crore)
| Particulars | FY26 | FY25 | FY24 |
|---|---|---|---|
| Revenue | 63.38 | 38.55 | 35.79 |
| EBITDA | 30.90 | 20.97 | 15.53 |
| PAT | 17.38 | 11.14 | 7.14 |
| Net Worth | 53.15 | 35.77 | 24.75 |
| Borrowings | 17.85 | 10.81 | 11.96 |
Chanakya Interpretation
Pramodini Medicare has delivered one of the strongest financial performances among recent SME healthcare IPOs. Revenue has grown by 64%, while PAT increased by 56% during FY26. The company has maintained exceptional operating margins, strong return ratios and a comfortable debt-equity ratio of 0.34, indicating a healthy balance sheet capable of supporting future expansion.
Business Quality Score
| Parameter | Rating |
|---|---|
| Business Model | ⭐⭐⭐⭐⭐ |
| Industry Outlook | ⭐⭐⭐⭐⭐ |
| Financial Performance | ⭐⭐⭐⭐⭐ |
| Management | ⭐⭐⭐⭐☆ |
| Balance Sheet | ⭐⭐⭐⭐☆ |
| Growth Potential | ⭐⭐⭐⭐⭐ |
IPO Proceeds & Why They Matter
| Purpose | Amount |
|---|---|
| Purchase of Medical Equipment for Existing & New Diagnostic Centres | Rs. 45.15 Cr |
| General Corporate Purposes & Strategic Expansion | Balance Amount |
Chanakya Interpretation
Unlike many SME IPOs where the proceeds are primarily used for working capital, Pramodini Medicare is investing the majority of the fresh capital in advanced medical equipment. This directly supports capacity expansion, enables the company to offer higher-value diagnostic services and strengthens its competitive position. Since diagnostic centres are equipment-intensive businesses, these investments have the potential to drive both revenue growth and operating leverage over the medium term.
Business Outlook
India’s diagnostic services industry continues to benefit from increasing healthcare awareness, preventive health check-ups, rising insurance penetration and growing demand for advanced imaging services. Government spending on healthcare infrastructure and the expansion of diagnostic facilities into Tier II and Tier III cities are creating long-term opportunities for organised players.
Pramodini Medicare is well positioned to benefit from these trends through its diversified business model, which includes government hospital PPP projects, private hospitals, PSUs and standalone diagnostic centres. The company’s expansion through new diagnostic equipment should further improve its service portfolio and revenue potential.
Strengths vs Concerns
| 👍 Strengths | ⚠ Concerns |
|---|---|
| Fast-growing diagnostics business | SME listing liquidity risk |
| Strong ROE & ROCE | Dependence on institutional contracts |
| High EBITDA & PAT margins | Continuous capex required for technology |
| Diversified revenue model | Competitive healthcare diagnostics sector |
| Expansion through fresh medical equipment | PPP contract renewal risk |
| Reasonable IPO valuation | Execution risk during expansion |
Who Should Apply?
| Investor Type | Suitability |
|---|---|
| Listing Gain Investors | ⭐⭐⭐⭐☆ |
| Long-Term Investors | ⭐⭐⭐⭐⭐ |
| Conservative Investors | ⭐⭐⭐☆☆ |
| Growth Investors | ⭐⭐⭐⭐⭐ |
Chanakya View
The IPO appears suitable for investors seeking exposure to India’s expanding healthcare diagnostics sector. Long-term investors may benefit from the company’s strong profitability, healthy return ratios and equipment-led expansion strategy. Listing-gain investors should monitor Pramodini Medicare IPO GMP and subscription demand before making the final decision.
Chanakya Final Verdict
Pramodini Medicare combines strong financial growth, excellent profitability, a healthy balance sheet and a scalable healthcare business model. The company’s diversified presence across government hospitals, private hospitals, PSUs and standalone diagnostic centres reduces dependence on any single customer segment.
The IPO also stands out because the fresh issue will largely fund medical equipment purchases, creating a tangible growth driver rather than merely strengthening working capital.
While investors should consider the normal risks associated with SME listings, the company’s 64% revenue growth, 56% PAT growth, ROE of 39.08%, ROCE of 34.66% and reasonable post-issue valuation of 14.97x make the issue attractive.
Chanakya Recommendation: 🟢 APPLY
Suitable for both listing gains (subject to healthy GMP) and long-term investors looking to participate in India’s rapidly growing diagnostics industry.
Frequently Asked Questions
What does Pramodini Medicare Limited do?
The company provides technology-enabled diagnostic services, including radiology, pathology and nuclear medicine, through hospitals, PPP projects, PSUs and standalone diagnostic centres.
What is the price band of Pramodini Medicare IPO?
The IPO is priced at Rs. 110 to Rs. 118 per share.
What is the minimum investment for retail investors?
Retail investors must apply for 2,400 shares, requiring an investment of approximately Rs. 2,83,200 at the upper price band.
When will Pramodini Medicare IPO open and list?
The IPO opens on 12 August 2026, closes on 14 August 2026, and is proposed to list on the NSE SME platform on 19 August 2026.
Should investors apply for Pramodini Medicare IPO?
Chanakya’s current recommendation is 🟢 Apply, considering its strong financial performance, attractive valuation and expansion-led use of IPO proceeds.
Summary
Pramodini Medicare IPO is a Rs. 69.04 crore NSE SME issue offering investors exposure to India’s fast-growing diagnostics sector. The company has delivered outstanding financial growth, industry-leading profitability and healthy return ratios. With most of the IPO proceeds earmarked for purchasing advanced medical equipment, the issue offers a clear expansion roadmap. Chanakya’s Overall Rating: ⭐⭐⭐⭐☆ (4/5) | Recommendation: 🟢 Apply.